Acadia Pharmaceuticals ACAD Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $375.65M-3.9% | $391M+49.7% | $261.17M+17.6% | $222.16M-2.9% | $228.88M+1.1% | ||
| $913K+4.8% | $871K-2.7% | $895K+0.1% | $894K-1.4% | $907K-1.4% | ||
| $55.45M+6.4% | $52.14M+5.6% | $49.35M-20.8% | $62.33M-2.1% | $63.68M-5.0% | ||
| —— | —— | —— | —— | $0— | ||
| $29.61M+30.3% | $22.72M+28.8% | $17.64M+363% | $3.81M-65.5% | $11.04M+2,239% | ||
| $8.91M-54.2% | $19.45M+2.5% | $18.98M-6.6% | $20.31M-53.2% | $43.36M-12.5% | ||
| -$5.85M-10.6% | -$5.29M-298% | $2.67M+1,140% | $215K+117% | -$1.24M+8.4% | ||
| $4.41M+123% | -$19.27M-124% | $79.9M+22.2% | $65.37M+11.3% | $58.75M-17.3% | ||
| $3.29M-14.4% | $3.85M-79.5% | $18.71M+4.6% | $17.9M+4.2% | $17.18M+3.5% | ||
| -$7.33M-778% | $1.08M+175% | -$1.43M-109% | $16.19M+86.3% | $8.69M+199% | ||
| —— | —— | —— | —— | —— | ||
| $10.89M0.0% | $10.89M-17.2% | $13.16M+3.0% | $12.78M+3.0% | $12.4M-17.1% | ||
| $5.06M-75.7% | $20.82M— | —— | —— | —— | ||
| —— | —— | $198.95M+5.9% | $187.91M+26.1% | $148.96M-5.6% | ||
| $9.9M+111% | $4.69M+312% | $1.14M+38.8% | $820K— | —— | ||
| $551.56M-20.4% | $692.57M+3.3% | $670.71M+8.6% | $617.65M+6.3% | $580.95M+15.0% | ||
| $449.23M-9.0% | $493.53M-1.2% | $499.63M+12.7% | $443.14M+12.7% | $393.25M+19.7% | ||
| —— | —— | —— | —— | $98.84M— | ||
| -$112.23M+62.9% | -$302.56M— | —— | —— | —— | ||
| $52.28M+4.8% | $49.88M+70.9% | $29.19M+45.7% | $20.03M+162% | $7.64M+11.6% | ||
| $52.28M+4.8% | $49.88M+70.9% | $29.19M+45.7% | $20.03M+162% | $7.64M+11.6% | ||
| $56K+115% | $26K+163% | -$41K+50.6% | -$83K+20.2% | -$104K-10.6% | ||
| —— | —— | —— | —— | $15.95M-88.1% | ||
| —— | $25.17M+5.9% | $23.76M+6.3% | $22.35M+6.7% | $20.93M+7.2% | ||
| $3.76M-30.7% | $5.42M-28.4% | $7.57M-17.8% | $9.22M-4.3% | $9.63M+3.5% | ||
| $10.89M0.0% | $10.89M-17.2% | $13.16M+3.0% | $12.78M+3.0% | $12.4M-17.1% | ||
| $913K+4.8% | $871K-2.7% | $895K+0.1% | $894K-1.4% | $907K-1.4% | ||
| —— | $0-100% | $36.63M-50.0% | $73.26M-33.3% | $109.89M-25.0% | ||
| $5.06M-75.7% | $20.82M— | —— | —— | —— | ||
| -$8.69M-0.3% | -$8.67M+2.1% | -$8.85M-9.1% | -$8.11M-2.9% | -$7.88M-5.0% | ||
| -$9.07M-39.2% | -$6.52M-81.2% | -$3.6M+49.5% | -$7.12M+6.7% | -$7.64M+2.0% | ||
| $2.3M-19.4% | $2.86M+42.4% | $2.01M+68.7% | $1.19M+154% | $468K+500% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $98.84M— | ||
| $449.23M-9.0% | $493.53M-1.2% | $499.63M+12.7% | $443.14M+12.7% | $393.25M+19.7% | ||
| —— | —— | —— | —— | —— | ||
| $56K+115% | $26K+163% | -$41K+50.6% | -$83K+20.2% | -$104K-10.6% | ||
| —— | $0-100% | $48.84M— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $539K+65.8% | $325K-23.5% | ||
| —— | $25.17M+5.9% | $23.76M+6.3% | $22.35M+6.7% | $20.93M+7.2% | ||
| —— | —— | $197.81M+5.7% | $187.09M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Acadia Pharmaceuticals's cash flow data come from?
- Every line is extracted from Acadia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.